Note 4. Fair Value of Financial Instruments

ASC 820 defines fair value, establishes a framework for measuring fair value, establishes a fair value hierarchy based on the observability of inputs used to measure fair value, and provides disclosure requirements for fair value measurements. The Company accounts for its investments at fair value in accordance with ASC 820. As of September 30, 2026 and December 31, 2025, the Company’s portfolio investments consisted primarily of investments in secured loans and equipment financings. The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

In accordance with ASC 820, the Company has categorized its investments based on the priority of the inputs to the valuation technique into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical investments (Level 1) and the lowest priority to unobservable inputs (Level 3). See “Note 2 – Summary of Significant Accounting Policies.”

As required by ASC 820, when the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3). Therefore, unrealized appreciation and depreciation related to such investments categorized within the Level 3 tables below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3).

The fair value determination of each portfolio investment categorized as Level 3 requires one or more of the following unobservable inputs:

The use of significant unobservable inputs creates uncertainty in the measurement of fair value as of the reporting date. The significant unobservable inputs used in the fair value measurement of the Company’s investments, are earnings before interest, tax, depreciation, and amortization (“EBITDA”) and revenue multiples (both projected and historic). Significant increases (decreases) in EBITDA and revenue multiple inputs in isolation would result in a significantly higher (lower) fair value measurement. Similarly, significant increases (decreases) in volatility inputs in isolation would result in a significantly higher (lower) fair value assessment. Conversely, significant increases (decreases) in weighted average cost of capital inputs in isolation would result in a significantly lower (higher) fair value measurement. However, due to the nature of certain investments, fair value measurements may be based on other criteria, such as third-party appraisals of collateral and fair values as determined by independent third parties, which are not presented in the tables below.

The methodology for determining the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The following table provides a summary of the significant unobservable inputs used to measure the fair value of the Level 3 portfolio investments as of September 30, 2026.

Fair Value of Financial Instruments Carried at Cost

As of September 30, 2026 and December 31, 2025, the carrying value of the KeyBank Credit Facility was approximately $485.7 million and $373.9 million, respectively. The carrying value of the KeyBank Credit Facility as of September 30, 2026 and December 31, 2025 approximates the fair value, which was estimated using a relative market yield approach with Level 3 inputs.

As of September 30, 2026 and December 31, 2025, the carrying value of the KeyBank Secured Term Loan Facility was approximately $173.7 million and $198.5 million, respectively, net of unamortized deferred financing costs of $1.2 million and $1.5 million, respectively. The carrying value of the KeyBank Secured Term Loan Facility as of September 30, 2026 and December 31, 2025 approximates fair value, which was estimated using a relative market yield approach with Level 3 inputs.

As of September 30, 2026, and December 31, 2025, the carrying value of the 4.25% Notes due 2026 (the “December 2026 Notes”) was approximately $74.9 million and $74.6 million, respectively, net of unamortized deferred financing costs of $0.1 million and $0.4 million, respectively. The December 2026 Notes have a fixed interest rate as discussed in “Note 5 – Borrowings.” The fair value of the Company’s December 2026 Notes as of September 30, 2026 and December 31, 2025 was approximately $69.3 million and $70.6 million, respectively, which was estimated using a relative market yield approach with Level 3 inputs.

As of September 30, 2026 and December 31, 2025, the carrying value of the Company's 7.875% Notes due March 2029 (the “March 2029 Notes”) was approximately $140.3 million and $139.7 million, respectively, net of unamortized deferred financing costs and premium of $1.9 million and $2.5 million, respectively. The March 2029 Notes have a fixed interest rate as discussed in “Note 5 – Borrowings.” The fair value of the Company's March 2029 Notes as of September 30, 2026 and December 31, 2025 was approximately $142.6 million and $143.3 million, respectively, based on the market closing price of the March 2029 Notes, which trade on the NYSE and NYSE Texas under the symbol “TRNZ”.

As of September 30, 2026 and December 31, 2025, the carrying value of the Company's 7.875% Notes due September 2029 (the “September 2029 Notes”) was approximately $119.9 million and $119.3 million, respectively, net of unamortized deferred financing costs and premium of $2.3 million and $2.9 million, respectively. The September 2029 Notes have a fixed interest rate as discussed in “Note 5 – Borrowings.” The fair value of the Company's September 2029 Notes as of September 30, 2026 and December 31, 2025 was approximately $122.5 million and $123.5 million, respectively, based on the market closing price of the September 2029 Notes, which trade on the NYSE and NYSE Texas under the symbol “TRNI”.

As of September 30, 2026 and December 31, 2025, the carrying value of the Company's Series A Senior Notes (the “Series A Notes”) was approximately $141.7 million and $141.3 million, respectively, net of unamortized deferred financing costs of $0.8 million and $1.2 million, respectively. The Series A Notes have a fixed interest rate as discussed in “Note 5 – Borrowings.” The fair value of the Company’s Series A Notes as of September 30, 2026 and December 31, 2025 was approximately $138.6 million and $143.8 million, respectively, which was estimated using a relative market yield approach with Level 3 inputs.

As of September 30, 2026 and December 31, 2025, the carrying value of the Company's 6.750% Notes due July 2030 (the “July 2030 Notes”) was approximately $122.6 million and $122.1 million, respectively, net of unamortized deferred financing costs and discount of $2.4 million and $2.9 million, respectively. The July 2030 Notes have a fixed interest rate as discussed in “Note 5 – Borrowings.” The fair value of the Company’s July 2030 Notes as of September 30, 2026 and December 31, 2025 was approximately $118.9 million and $124.8 million, respectively, which was estimated using a relative market yield approach with Level 3 inputs.

As of September 30, 2026, the carrying value of the Company's 7.00% Notes due May 2031 (the “May 2031 Notes”) was approximately $294.2 million, net of unamortized deferred financing costs and discount of $5.8 million. The May 2031 Notes have a fixed interest rate as discussed in “Note 5 – Borrowings.” The fair value of the Company’s May 2031 Notes as of September 30, 2026 was approximately $291.4 million, which was estimated using a relative market yield approach with Level 3 inputs.